ArticlePloS one2014
Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01014845 (A Phase 3, Randomized, Double-blind, Placebo), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Effectiveness of a hepatitis E vaccine against medically-attended symptomatic infection in HBsAg-positive adults from a test-negative design study.Nature communications · 2025Trial
- Cost-effectiveness analysis of hepatitis E screening and vaccination: targeting vulnerable populations in outbreak and sporadic settings in China.Emerging microbes & infections · 2026Article
- Trends and projections of hepatitis E incidence in Jiangsu Province of eastern China from 2007 to 2021: An analysis based on age-period-cohort models.Infectious Disease Modelling · 2025Article
- Article
- Global Trends and Cross-country Inequalities of Acute Hepatitis E in the Elderly, 1990-2021: A Comprehensive Analysis.Journal of clinical and translational hepatology · 2025Article
- Cost-Effectiveness of Hepatitis E Vaccination Strategies among Patients with Chronic Liver Diseases in China: A Model-Based Evaluation.Vaccines · 2024Article
- Review
- Prevalence, Genetic Diversity, and Quantification of the RNA Genome of the Hepatitis E Virus in Slaughtered Pigs in Serbia.Animals : an open access journal from MDPI · 2024Article
- Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study.Emerging microbes & infections · 2023Article
- Hepatitis E virus seroprevalence among employees in catering and public place industries in Nanjing, China.Epidemiology and infection · 2023Article
- The prevention strategies of swine viruses related to xenotransplantation.Virology journal · 2023Review
- [Prophylactic vaccines for hepatitis type E].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Prophylactic Hepatitis E Vaccine.Advances in experimental medicine and biology · 2023Article
- Development of a competitive ELISA for detecting antibodies against genotype 1 hepatitis E virus.Applied microbiology and biotechnology · 2021Article
- Review
- Dynamics of Hepatitis E Virus (HEV) Antibodies and Development of a Multifactorial Model To Improve the Diagnosis of HEV Infection in Resource-Limited Settings.Journal of clinical microbiology · 2021Article
- Autochthonous and Travel Acquired Hepatitis E Virus in Australia.Frontiers in microbiology · 2021Article
- Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.The lancet. Gastroenterology & hepatology · 2020Review
- Prognostic Significance of End-Stage Liver Diseases, Respiratory Tract Infection, and Chronic Kidney Diseases in Symptomatic Acute Hepatitis E.Frontiers in cellular and infection microbiology · 2020Article
- Seroprevalence of AIH-related autoantibodies in patients with acute hepatitis E viral infection: a prospective case-control study in China.Emerging microbes & infections · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis E is caused by two viral genotype groups: human types and zoonotic types. Current understanding of the epidemiology of the zoonotic hepatitis E disease is founded largely on hospital-based studies.
methodsThe epidemiology of hepatitis E was investigated in a community-based surveillance study conducted over one year in a rural city in eastern China with a registered population of 400,162.
resultsThe seroprevalence of hepatitis E in the cohort was 38%. The incidence of hepatitis E was 2.8/10,000 person-years. Totally 93.5% of the infections were attributed to genotype 4 and the rest, to genotype 1. Hepatitis E accounted for 28.4% (102/359) of the acute hepatitis cases and 68.9% (102/148) of the acute viral hepatitis cases in this area of China. The disease occurred sporadically with a higher prevalence during the cold season and in men, with the male-to-female ratio of 3∶1. Additionally, the incidence of hepatitis E increased with age. Hepatitis B virus carriers have an increased risk of contracting hepatitis E than the general population (OR = 2.5, 95%CI 1.5-4.2). Pre-existing immunity to hepatitis E lowered the risk (relative risk = 0.34, 95% CI 0.21-0.55) and reduced the severity of the disease.
conclusionsHepatitis E in the rural population of China is essentially that of a zoonosis due to the genotype 4 virus, the epidemiology of which is similar to that due to the other zoonotic genotype 3 virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.